Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Buy Rating Justified: Acumen Pharmaceuticals' Promising Position in Alzheimer's Treatment Market
Express News | HC Wainwright & Co. Reiterates Buy on Acumen Pharmaceuticals, Maintains $15 Price Target
Acumen Pharmaceuticals' Sabirnetug: A Novel Approach in Alzheimer's Disease Treatment Warrants a Buy Rating
Acumen Pharmaceuticals Inc (ABOS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
Q1 2024 Acumen Pharmaceuticals Inc Earnings Call
Acumen Pharmaceuticals | 10-Q: Quarterly report
Earnings Call Summary | Acumen Pharmaceuticals(ABOS.US) Q1 2024 Earnings Conference
The following is a summary of the Acumen Pharmaceuticals, Inc. (ABOS) Q1 2024 Earnings Call Transcript:Financial Performance:Acumen Pharmaceuticals reported cash and marketable securities worth approx
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
GainersCareCloud (NASDAQ:CCLDO) stock moved upwards by 46.1% to $15.5 during Tuesday's pre-market session. Syra Health (NASDAQ:SYRA) shares increased by 33.08% to $1.77. The market value of their outs
Acumen Pharmaceuticals Begins Phase 2 Trial and Updates Finances
Express News | Acumen Pharmaceuticals Inc Q1 Shr View $-0.26 -- Lseg Ibes Data
Express News | Acumen Pharmaceuticals Inc - Qtrly Shr Loss $0.25
Express News | Acumen Pharmaceuticals Inc - Cash Is Expected to Support Current Clinical and Operational Activities Into First Half of 2027
Express News | Acumen Pharmaceuticals Q1 2024 GAAP EPS $(0.25) Beats $(0.27) Estimate
Express News | Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
Acumen Pharmaceuticals 1Q Loss/Shr 25c >ABOS
Acumen Pharmaceuticals 1Q Loss/Shr 25c >ABOS
Optimistic Buy Rating for Acumen Pharmaceuticals Based on Strategic Alzheimer's Treatment Approach and Promising Clinical Prospects
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta
Acumen Pharmaceuticals to Participate in the 2024 Bank of America Healthcare Conference
Acumen Pharmaceuticals Doses 1st Patient in Alzheimer's Disease Drug Study
Acumen Pharmaceuticals (ABOS) said Wednesday that it has dosed the first patient in the phase 2 study of sabirnetug for patients of early Alzheimer's disease. The phase 2 trial is currently enrolling